RT Journal Article
SR Electronic
T1 Impact of nighttime and early morning symptoms on HRQoL and work productivity of COPD patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3632
VO 42
IS Suppl 57
A1 Sean Sullivan
A1 Judith Stephenson
A1 Qian Cai
A1 Hiangkiat Tan
A1 Abhishek Kavati
A1 Michelle Mocarski
A1 Jalpa Doshi
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3632.abstract
AB INTRODUCTIONThis study assessed impact of nighttime (NT) and early morning (EM) symptoms on health-related quality of life (HRQoL) and work productivity of employed COPD patients.METHODSEmployed patients ≥40 years with ≥1 ICD-9-CM COPD diagnosis code medical claim or ≥1 COPD maintenance medication pharmacy claim were identified from the HealthCore Integrated Research Database. Respondents completed a survey assessing HRQoL (Short Form-12 version 2 [SF-12v2], COPD Assessment Test [CAT]) and productivity (Work Productivity and Activity Impairment [WPAI] questionnaire); indirect costs were calculated by monetizing WPAI items. Respondents were classified based on NT and/or EM symptom experience in the past week and enrollment was stratified based on NT/EM symptoms. Groups were compared via ANOVA and chi-square.RESULTSRespondents (N=437) reported having both (39.6%), either (33.4%), or neither NT/EM symptoms (27.0%). Compared to respondents without NT/EM symptoms, those with both/either reported worse HRQoL (lower PCS, MCS scores, higher CAT scores; p<0.01). Respondents with both reported significant work productivity loss (3% absenteeism, 21% presenteeism, 22% overall work impairment), and averaged 27% daily activity impairment. Average monetary impact of COPD-related work absenteeism/presenteeism was significantly higher for patients with both symptoms vs those without ($31/week vs $2, p<0.05).CONCLUSIONSCOPD patients with NT and/or EM symptoms had lower HRQoL, while those with both reported greater work productivity loss and greater activity impairment vs patients with no symptoms. Improved disease management may lower the economic impact on patients, employers, and the healthcare system.